Skip to main content
. 2019 Feb 19;10(4):587–592. doi: 10.1111/1759-7714.13010

Table 1.

Case reports of symptomatic deterioration associated with serous effusion

Author (year) Gender Age Pathology PD‐1/PD‐L type PD‐L1 expression Initial symptom deterioration time Serous effusion Response time
Hochmair et al. (2017)7 Male 63 Adenocarcinoma Pembrolizumab 90% Eight weeks Pleural effusion Six weeks
Hochmair et al. (2017) 7 Female 63 Adenocarcinoma Pembrolizumab 90% Five weeks Pleural effusion Four weeks
Kolla & Patel (2016)8 Male 46 Small cell carcinoma Nivolumab NR Eight weeks Pleural effusion, pericardial effusion Eight weeks
Kolla & Patel (2016)8 Female 54 Adenocarcinoma Nivolumab NR Seven weeks Pleural effusion, pericardial effusion Two weeks

NR, no response.